We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Global Digital Pathology Market Worth USD 1,052 Million by 2022

By LabMedica International staff writers
Posted on 25 Jul 2016
Print article
The global digital pathology market will reach USD 1,052 million by 2022, driven by the growing popularity of virtual slides over physical slides, technological advancements, and cost-effective products, with North America accounting for the major share.

According to a new Allied Market Research (Portland OR, USA) report, other factors such as workflow efficiency, analysis efficiency, improved productivity and patient care, and accuracy are also contributing to the market growth. However, lack of reimbursement policies, inadequate infrastructure, and pending product approvals are restraining the growth of the global digital pathology market.

Digitalization of pathology, where glass slides are converted into digital images for easy viewing, analysis, storage, and management of collected data, has resulted in automation of tests during diagnosis, thus saving cost and efforts. For instance, pathologists can now perform tests using a single digital instrument instead of five instruments required earlier.

Based on product, the market is segmented into whole slide imaging (WSI), image analysis informatics, information management system storage & communication, and others. WSI is the major segment and is expected to grow at a CAGR of 14.8% from 2014 to 2022, due to its diversified use in surgical pathology, clinical diagnosis, consultation, and education, as well as in proficiency testing, which is a part of cytopathology.

Within the WSI segment, the scanners/digitizers segment accounted for the largest share in 2015, while reagents is projected to be the fastest growing segment at a CAGR of 15.3% from 2014 to 2022. The image analysis-informatics segment is the fastest growing segment, growing at a CAGR of 25.2%, and along with the WSI segment, it comprises about three-fourths of the total market.

Based on end user, the market is segmented into educational institutes, hospitals and diagnostic centers; and pharmaceutical & biotechnology companies. In 2015, hospitals and diagnostic centers and pharmaceutical & biotechnology end user segments together accounted for a share of more than 70% of the market. Pharmaceutical & biotechnology companies are projected to be the fastest growing end use segment, growing at a CAGR of 19.9% from 2014 to 2022.

In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In 2015, Asia Pacific and LAMEA together accounted for about 20% of the market. The German digital pathology market is expected to reach about USD50 million by 2022, growing at a CAGR of 14.5% over the period 2014 to 2022.

In 2015, North America accounted for the major share of the overall digital pathology market and is expected to grow at a CAGR of 14.7% from 2014 to 2022, driven mainly by a large number of hospitals and clinics adopting digital pathology procedures for accurate results and improved efficiency. In North America, WSI is expected to dominate the market followed by image analysis-informatics. However, Asia-Pacific is expected to grow rapidly at a CAGR of 26.6%, with the major contribution to come from China due to its cost-effective products and image analysis-informatics to be the fastest growing segment in the region with a CAGR of 34.9%.

Currently, companies are adopting collaborations, product launches, and agreements as their key development strategies in the market. An increase in the number of initiatives for commercializing cost-efficient digital pathology systems is expected to offer profitable growth opportunities for service providers in the future.

The key companies in the global digital pathology market are Definiens AG (Munich, Germany), Visiopharm (Hørsholm, Denmark), Indica Labs (Corrales, NM, USA), Digipath, Wichita, KS, USA), Danaher Corporation (Leica Microsystem) (Washington, D.C., USA), Koninklinje Philips N.V. (Amsterdam, Netherlands), Hamamatsu Photonics K. K. (Hamamatsu, Japan), PerkinElmer, Inc. (Waltham, MA; USA), Nikon Corporation (Tokyo, Japan), Pixcelldata Ltd. (Dublin 2, Ireland), and Glencoe Software Inc. (Seattle, WA, USA).

Related Links:
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.